A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with nonsteroidal anti-inflammatory drugs (NSAID).
Phase 3
- Conditions
- Patients that require long-term NSAID treatment to manage pain.
- Registration Number
- JPRN-jRCT2080220485
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 602
Inclusion Criteria
1) The patient was on NSAID treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.
2) The patient was confirmed to have a history of gastric
ulcer or duodenal ulcer (combined gastric and duodenal
ulcer is also possible).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method